)
FluoGuide (FLOU) investor relations material
FluoGuide Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved regulatory alignment with FDA for lead indications and U.S. Phase 2 trial of FG001, de-risking the path to approval and commercialization.
Positive Phase II and interim results for FG001 in high-grade glioma, meningioma, low-grade glioma, and head and neck cancer; expanded partnerships with Olympus, ZEISS, and other MedTech firms.
Strengthened management and leadership team, completed capital raises to fund clinical and regulatory milestones.
Financial highlights
Full-year net loss of DKK 39.5 million, with Q4 2025 net loss of DKK 13.1 million.
Assets totaled DKK 88 million, with DKK 79 million in cash and securities at year-end.
Equity stood at DKK 55 million, with a loan of DKK 28 million and working capital payables of DKK 5 million.
Cash flow from financing activities in 2025 was DKK 97.0 million, mainly from capital increases and credit facilities.
Market cap at year-end DKK 389 million, up from DKK 370 million a year earlier.
Outlook and guidance
First U.S. patient enrollment in registration trial expected in the first half of 2026.
Interim results from low-grade glioma and head and neck studies anticipated in the second half of the year.
Plans to present a comprehensive brain tumor strategy and PDT optimization plan later in the year.
Expects to secure an additional commercial partnership during the year.
Long-term objective is first U.S. drug approval for FG001 and broadening its use as a photosensitizer.
Next FluoGuide earnings date
Next FluoGuide earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
FluoGuide is a Danish clinical-stage biotech company specializing in the development of products used to improve cancer surgery. FluoGuide's main product, FG001, is designed to illuminate brain cancer cells during surgery, enabling surgeons to distinguish them more easily from healthy tissue. FG001 is designed to bind specifically to cancer cells, making them visible under a special light during surgery. This aims to reduce the risk of leaving cancerous tissue behind, potentially increasing the success rate of surgeries. The company is also actively researching whether its fluorescent technology can be employed to potentially improve surgery outcomes for a variety of different cancers. FluoGuide is headquartered in Copenhagen, and its shares are listed on Nasdaq Stockholm.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)